Pituitary tumours: Findings from whole genome analyses

Endocrine-Related Cancer

Volumn 13, Issue 3, 2006, Pages 707-716

  Farrell, W E ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; NOGGIN;

CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA DAMAGE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; GROWTH DISORDER; HETEROZYGOSITY LOSS; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; METHYLATION; MICROSATELLITE MARKER; NONHUMAN; PATHOGENESIS; REVIEW;

DNA DAMAGE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; PITUITARY NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 33751097773     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01131     Document Type: Review

References (52)

1. Abbud RA, Takumi I, Barker EM, Ren SG, Vhen DY, Wawroswsky K & Melmed S 2005 Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Molecular Endocrinology 19 1383-1391.
2. Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A & Klibanski A 1990 Clinically non-functional pituitary tumors are monoclonal in origin. Journal of Clinical Investigation 86 336-340.
3. Asa SL & Ezzat S 2002 The pathogenesis of pituitary tumors. Nature Reviews Cancer 2 836-849.
4. Asa SL & Ezzat S 2005 Genetics and proteomics of pituitary tumors. Endocrine 28 43-47.
5. Bahar A, Bicknell JE, Simpson DJ, Clayton RN & Farrell WE 2004a Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 23 936-944.
6. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, Holley S, Mourtada-Maarabouni M, Williams GT, Clayton RN & Farrell WE 2004b Isolation and characterization of a novel pituitary tumor apoptosis gene. Molecular Endocrinolgy 18 1827-1839.
7. Bates AS, Farrell WE, Bicknell EJ, Talbot AJ, Broome JC, Perrett CW, Thakker RV & Clayton RN 1997 Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Journal of Clinical Endocrinology and Metabolism 82 818-824.
8. Buch HN, Raskauskiene D, Bahar A, Bicknell EJ, Farrell WE & Clayton RN 2004 Prediction of recurrence of nonfunctioning pituitary tumours by loss of heterozygosity analysis. Clinical Endocrinology 61 19-25.
9. +/- pituitary tumorigenesis. Molecular Endocrinology 19 2371-2379.
10. Daniely M, Aviram A, Adams EF, Buchfelder M, Barkkai G, Fahlbusch R, Goldman B & Friedman E 1998 Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. Journal of Clinical Endocrinology Metabolism 83 1801-1805.
11. Draghici S, Khatri P, Eklund AC & Szallasi Z 2006 Reliability and reproducibility issues in DNA microarray measurements. Trends in Genetics 22 101-109.
12. Evans C-O, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS & Oyesiku NM 2001 Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. Journal of Clinical Endocrinology and Metabolism 86 3097-3107.
13. Fan X, Paetau A, Aalto Y, Valimaki M, Sane T, Poranen A, Castresana JS & Knuutila S 2001 Gain of chromosome 3 and loss of 13q are frequent alterations in pituitary adenomas. Cancer Genetics and Cytogenetics 128 97-103.
14. Farrell WE 2005 Epigenetic mechanisms of tumorigenesis. Hormones Metabolism Research 37 361-368.
15. Fathallah-Shaykh HM 2005 Microarrays applications and pitfalls. Archives of Neurology 62 1669-1672.
16. Finelli P, Giardino D, Rizzi N, Buiatiotis S, Virduci T, Franzin A & Losa-Larizza L 2000 Non-random trisomies of chromosome 5, 8 and 12 in prolactinomas sub-type of pituitary adenomas; conventional cytogenetic and interphase FISH study. International Journal of Cancer 86 344-350.
17. Frost SJ, Simpson DJ, Clayton RN & Farrell WE 1999 Transfection of an inducible p16/CDKN2A construct mediated reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line. Molecular Endocrinology 13 1801-1810.
18. Giacomini D, Paez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Cherum A, Berner S, Losa M, Buch felder M et al. 2006 Bone morphogenetic protein-4: involvement in the retinoic acid inhibitory action. Endocrinology 147 247-256.
19. Goidin D, Kappeler L, Perrot J, Epelbaum J & Gourdji D 2000 Differential pituitary gene expression profiles associated- to aging and spontaneous tumors as revealed by rat cDNA expression array. Endocrinology 141 4805-4808.
20. Gonzalgo ML, Liang G, Spruck CH, Zingg JM, Rideout WH & Jones PA 1997 Identification and characterisation of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Research 57 594-599.
21. Harada K, Nishizaki T, Ozaki S, Kubota H, Harada K, Okamura T, Ito H & Sasaki K 1999 Cytogenetic alterations in pituitary adenomas detected by comparative genomic hybridization. Cancer Genetics and Cytogenetics 112 38-41.
22. Heaney AP & Melmed S 2004 Molecular targets in pituitary tumours. Nature Reviews in Cancer 4 285-295.
23. Herman V, Fagin J, Gonsky R, Kovaks K & Melmed S 1990 Clonal origin of pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 71 1427-1433.
24. Horwitz GA, Miklovsky I, Heaney AP, Ren SG & Melmed S 2003 Human pituitary transforming gene (PTTG1) motifs suppresses prolactin expression. Molecular Endocrinology 17 600-609.
25. Hui ABY, Pang JCS, Ko C-W & Ng H-K 1999 Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridisation. Human Pathology 30 1019-1023.
26. Hu YF, Kaplow J & He Y 2005 From traditional biomarkers to transcriptome analysis in drug development. Current Molecular Medicine 5 29-38.
27. Iovanna JL 2002 Expression of the stress-associated protein p8 is a requisite for tumour development. International Journal of Gastrointestinal Cancer 31 89-98.
28. Ito Y, Yoshida H, Motoo Y, Miyoshi E, Iovanna JL, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuku F, Matsuura N, Kuma K & Miyauchi A 2003 Expression and cellular localization of p8 protein in thyroid neoplasms. Cancer Letters 201 237-244.
29. Ito Y, Yoshida H, Motoo Y, Iovanna JL, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuku F, Matsuzuka F, Kuma K & Miyauchi A 2005 Expression of p8 protein in medullary thyroid carcinoma. Anticancer Research 25 3419-3423.
30. Jones PA & Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nature Reviews in Genetics 3 415-428.
31. Kovacs K & Hovarth E 1987 Pathology of pituitary tumors. Endocrinology and Metabolism Clinics of North America 16 529-551.
32. Levy A & Lightman S 2003 Molecular defects in the pathogenesis of pituitary tumours. Frontiers in Neuroendocrinology 24 94-127.
33. Melmed S 2003 Mechanisms of pituitary tumorigenesis: the plastic pituitary. Journal of Clinical Investigation 112 1603-1618.
34. Metzger AK, Mohapatra G, Minn YA, Bollen AW, Lamborn K, Waldman FM, Wilson CB & Feuerstein BG 1999 Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in primary adenomas by comparative genomic hybridization. Journal of Neurosurgery 90 306-314.
35. Mohammed HP, Abbud RA, Parlow AF, Lewin JS & Nilson JH 2004a Targeted overexpression of luteinizing hormone causes ovary-dependent functional adenomas restricted to cells of the Pit-1 lineage. Endocrinology 144 4626-4636.
36. Mohammed HP, Seachrist DD, Quirk CC & Nilson JH 2004b Reexpression of p8 contributes to tumorigenic properties of pituitary cells and appears in a subset of prolactinomas in transgenic mice that hypersecrete luteinizing hormone. Molecular Endocrinology 18 2583-2593.
37. Moreno CS, Evans C-O, Zhan X, Okor M, Desiderion DM & Oyesiku NM 2005 Novel molecular signaling and classification of human clinically non-functional pituitary adenomas identified by gene expression profiling and proteomic analysis. Cancer Research 65 10214-10222.
38. Morris DG, Musat M, Czirjak S, Hanzely Z, Lillington DM, Korbonits M & Grossman AB 2005 Differential gene expression in pituitary adenomas by oligonucleotide array analysis. European Journal of Endocrinology 153 143-151.
39. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C et al. 2001 Retinoic acid prevent experimental Cushing syndrome. Journal of Clinical Investigation 108 1123-1131.
40. Paez-Pereda M, Giacommini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chermin A, Goldberg V, Goya R Hentges ST et al. 2003 Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. PNAS 100 1034-1039.
41. Pei L & Melmed S 1997 Isolation and characterization of pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 11 433-441.
42. Pernicone PJ, Scheithauer B, Sebo TJ, Kovaks KT, Hovath E, Young WF, Jr, Lloyd RV, Davis DH, Guthrie BH & Schoene WC 1997 Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79 804-812.
43. Rickert CH, Busch BD-DG, Moskopp D, Albert FK, Rama B & Paulus W 2001 Increased chromosomal imbalance in recurrent pituitary adenomas. Acta Neuropathologica 102 615-620.
44. Simpson DJ, McNicol dAM, Murray DC, Bahar A, Turner HE, Wass JAH, Esiri MM, Clayton RN & Farrell WE 2004 Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clinical Cancer Research 10 1780-1788.
45. Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 82 3141-3147.
46. Trautmann K, Thakker RV, Ellison DW, Ibrahim A, Lees PD, Harding B, Fischer C, Popp S, Bartmram CR & Jauch A 2001 Chromosomal aberrations in sporadic pituitary tumors. International Journal of Cancer 91 809-814.
47. Wood WM, Sapapura VD, Dowding JM, Woodmansee WM, Haakinson DJ, Gordon DF & Ridgway EC 2002 Early gene expression changes preceding thyroid hormone-induced involution of a thyrotrope tumor. Endocrinology 143 347-359.
48. Yin D, Kondo S, Takeuchi J, Morimura T & Vaux DL 1994 Bcl-2 gene prevents apoptosis in murine ACTH-secreting adenoma cells induced by bromocriptine. International Journal of Oncology 4 187-191.
49. Yin D, Tamaki N, Kokunai T, Yasuo K & Yonezawa K 1999 Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression. Journal of Clinical Neuroscience 6 326-331.
50. Zhang X, Howitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD & Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 761-767.
51. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B & Klibanski A 2002 Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 87 1262-1267.
52. Zhao J, Dahle D, Zhou Y, Zhang X & Klibanski A 2005 Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 90 2179-2186.